Kinetics of serum soluble tumour necrosis factor receptor (TNF-R) type-I and type-II after a single interferon-alpha (IFN-α) injection in chronic hepatitis C

Clinical and Experimental Immunology

Volumn 117, Issue 3, 1999, Pages 556-560

  Fabris, C ^b   Del Forno, M ^b   Falleti, E ^b   Toniutto, P ^b   Pirisi, Mario ^a  

^a Ospedale di Careggi   (Italy)

^b NONE

Author keywords

Cytokine; Hepatitis C; Interferon alpha; Tumour necrosis factor

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; RECEPTOR SUBTYPE; RECOMBINANT ALPHA2B INTERFERON; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; IMMUNOREGULATION; IMMUNOTHERAPY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032783225     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00992.x     Document Type: Article

References (34)

1. 1 Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter, randomized, controlled trial. N Engl J Med 1980; 321:1501-5.
2. 2 Di Bisceglic AM, Martin P, Kassianides C et al. Recombinant interferon alpha therapy for chronic hepatitis C: a randomized, double-blind, placebo controlled trial. N Engl J Med 1989; 321:1506-10.
3. 3 Peters M. Mechanism of action of interferons. Semin Liver Dis 1989; 9:235-9.
4. 4 Stoffa R, Burgess SJ, Peters M. Clinical pharmacology of anti-viral agents. In: Zakim D, Boyer TD, eds. Hepatology. A textbook of liver disease. Philadelphia: W.B. Saunders Co., 1996:1293-9.
5. 5 Corssmit EP, Heijligenberg R, Hack CE, Endert E, Sauerwein HP, Romijn JA. Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans, Clin Exp Immunol 1997; 107:359-63.
6. 6 Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997; 112:1017-2.
7. 7 Larrea E, Garcia N, Qian C, Civeira MP, Prieto J. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996; 23:210-7.
8. 8 Fabris C, Soardo G, Falleti E et al. Relationship among hepatic inflammatory changes, circulating levels of cytokines, and response to IFN-α in chronic hepatitis C. J Interior Cytok Res 1998; 18:705-9.
9. 9 Van Bladel S, Libert C, Fiers W. Interleukin-6 enhances the expression of tumor necrosis factor receptors on hepatoma cells and hepatocytes. Cytokine 1991; 3:149-54.
10. 10 Dickensheets HL, Freeman SL, Smith MF, Donnelly RP. Interleukin-10 upregulates tumor necrosis factor receptor type-II (p75) gene expression in endotoxin-stimulated human monocytes. Blood 1997; 90:4162-71.
11. 11 Gerain J, Lienard D, Pampallona S et al. Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion. Cytokine 1997; 9:1034-42.
12. 12 Toniutto P, Pirisi M, Tisminetzky SG et al. Discordant results of hepatitis C virus genotyping by procedures based on amplification of different genomic regions. J Clin Microbiol 1996; 34:2382-5.
13. 13 Altman DG. Practical statistics for medical research. London: Chapman & Hall, 1991: 431-3.
14. 14 Offner P, Philippe J, Vogelaars D et al. Serum tumor necrosis factor levels in patients with infectious disease and septic shock. J Lab Clin Med 1990; 116:100-5.
15. 15 Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89:4845-9.
16. 16 Digel W, Porzsolt F, Schmid M, Herrmann F, Lesslauer W, Brockhaus M. High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia. J Clin Invest 1992; 89:1690-3.
17. 17 Aderka D, Englemann H, Hornik V et al. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res 1991; 51:5602-7.
18. 18 Cinat ME, Waxman K, Granger GA, Pearce W, Annas C, Daughters K. Trauma causes sustained elevation of soluble tumor necrosis factor receptors. J Am Coll Surg 1994; 179:529-37.
19. 19 Zangerle R, Gallati H, Sareletti M et al. Increased serum concentrations of soluble tumor necrosis factor receptors in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr 1994; 7:79-85.
20. 20 Kallinowski B, Haseroth K, Marinos G et al. Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 1998; 111:269-77.
21. 21 Krajesi P, Wold WS. Inhibition of tumor necrosis factor and interferon triggered responses by DNA viruses. Semin Cell Dev Biol 1998; 9:351-8.
22. 22 Bertoletti A, D'Elios MM, Boni C et al. Different cytokine profiles of intrahepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 1997; 112:193-9.
23. 23 Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13:29-60.
24. 24 Ning Q, Brown D, Parodo J et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fg12 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998; 160:3487-93.
25. 25 Gane EJ, Lo SK, Riordan SM et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998; 27:1403-7.
26. 26 Ikeda T, Lever AML, Thomas MC. Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection in adult life. Hepatology 1986; 6:962-5.
27. 27 Pirisi M, Fabris C, Toniutto P et al. Endogenous interferon alpha and outcome of interferon treatment in patients with chronic hepatitis C. Dig Dis Sci 1997; 42:767-71.
28. 28 Fukuda R, Ishimura N, Kushiyama Y et al. Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver. J Hepatol 1997; 26:455-61.
29. 29 Kemper O, Derre J, Cherif D, Engelmann H, Wallach D, Berger R. The gene for the type II (p75) tumor necrosis factor receptor (TNF-RII) is localized on band 1p36.2p36.3. Hum Genet 1991; 87:623-4.
30. 30 Derre J, Kemper O, Cherif D, Nophar Y, Berger R, Wallach D. The gene for the type 1 tumor necrosis factor receptor (TNF-R1) is localized on band 12p13. Hum Genet 1991; 87:231-3.
31. 31 Mylius-Spencker H, Winzen R, Resch K, Holtmann H. Regulation of expression of transmembrane and soluble 75 kDa tumor necrosis factor receptors by interferon-gamma and granulocyte-macrophage colony-stimulating factor involves transcriptional activation. Eur Cytokine Netw 1997; 8:351-8.
32. 32 Sato T, Selleri C, Anderson S, Young NS, Maciejewski JP. Expression and modulation of cellular receptors for interferon-gamma, tumour necrosis factor, and Fas on human bone marrow CD34+ cells. Br J Haematol 1997; 97:356-65.
33. 33 Ruby J, Bluethmann H, Peschon JJ. Antiviral activity of tumor necrosis factor (INF) is mediated via p55 and p75 TNF receptors. J Exp Med 1997; 186:1591-6.
34. 34 Herbein G, Montaner LJ, Gordon S. Tumor necrosis factor alpha inhibits entry of the human immunodeficiency virus type 1 into primary human macrophages: a selective role for the 75-kilodalton receptor. J Virol 1996; 70:7388-97.